Poxel Secures €3.75M in Additional Bond Financing Under Continuation Plan
Event summary
- Poxel signed a €3.75M Tranche D PDR bond agreement with IPF Partners on March 25, 2026, as part of its continuation plan approved by the Lyon Commercial Court.
- The financing includes a 0% cash interest rate but a 35% capitalized interest rate and a 10% commitment fee.
- Tranche D PDR is secured by trusts and a privilege under French Commercial Code, with an availability period until 2031.
- Poxel plans additional financing measures, including a €5M equity line from IRIS and capital increases with shareholders.
- The company aims to reduce debt and secure operations through multiple financing operations and cost reductions.
The big picture
Poxel's €3.75M bond financing is a critical step in its continuation plan, reflecting the company's efforts to stabilize its financial position amid high interest rates and stringent conditions. The multiple financing measures, including equity lines and capital increases, indicate a strategic shift towards reducing debt and securing long-term operations. This move is part of a broader trend in the biopharmaceutical sector where companies leverage diverse financing tools to navigate financial challenges and sustain growth.
What we're watching
- Financial Stability
- How Poxel will manage the high capitalized interest rate of 35% and the 10% commitment fee under the Tranche D PDR bond.
- Execution Risk
- Whether Poxel can achieve the Imeglimin sales targets required to draw down the Tranche D PDR financing.
- Debt Reduction
- The pace at which Poxel can reduce its debt through the planned capital increases and other financing operations.